Adipotide
Adipotide is a radically aggressive, experimental peptidomimetic engineered to physically eradicate white adipose tissue. Rather than simply suppressing appetite like a GLP-1, it is designed to assassinate the very blood supply feeding fat cells. While it demonstrated shockingly rapid and massive fat loss in primate models, it is essentially a highly targeted biological weapon that carries profound, severe risks of renal toxicity and kidney damage.
Quick Stats
Scientific Data
Mechanism of Action
Adipotide (CKGGRAKDC-GG-D(KLAKLAK)2) is a pro-apoptotic peptide that selectively targets the vasculature feeding white adipose tissue. It binds to prohibitin on the surface of fat blood vessels and delivers a cell-killing D(KLAKLAK)2 sequence, causing mitochondrial disruption and apoptosis of the endothelial cells supplying fat depots. This cuts off nutrient supply to adipocytes, causing fat cell death and rapid weight loss. Phase I/II primate studies showed 11% body weight reduction over 4 weeks — one of the most aggressive mechanisms of any anti-obesity agent.
Source: PMID: 22100857
Dosing Protocol
| Typical Dose | 0.5-1 mg/kg (research) |
| Frequency | Per study protocol |
| Half-Life | ~2-4 hours (estimated) |
| Common Vial Sizes | 5 mg |
Dosing Protocols
Primate Research Dose
Administration
Expected Timeline
Who Is It For?
Obesity (Preclinical Only)
HighDramatic fat loss via vascular apoptosis mechanism — but renal toxicity observed in primates at therapeutic doses.
Reconstitution Example
Safety & Considerations
RESEARCH ONLY. Renal toxicity observed in primate studies at effective doses. No human clinical trials have been approved. Not for human use.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Dosing Quick Reference
Frequently Asked Questions
Has adipotide been tested in humans?▼
How does adipotide differ from GLP-1 drugs?▼
References
- Kim DH et al. “"Targeted elimination of senescent cells by adipotide".” Science Translational Medicine (2011).
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code